{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-006012","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.356209+00:00","generated_at":"2026-05-25T15:37:55.632839+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Allarity Therapeutics authorizes $5M share repurchase program through Feb 2026","bullets":["Board authorized repurchase of up to $5M of common stock; program runs through Feb 28, 2026.","CEO Thomas Jensen cites confidence in stenoparib’s clinical potential and long-term vision.","Company says sufficient cash position maintains runway into 2026, unaffected by buyback.","Repurchases discretionary; may be made via open market or other methods under Rule 10b-18.","Allarity is a Phase 2 clinical-stage biotech developing dual PARP/Wnt inhibitor stenoparib."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-006012","json":"https://secwatch.observer/filing/0001437749-25-006012.json","markdown":"https://secwatch.observer/filing/0001437749-25-006012.md","text":"https://secwatch.observer/filing/0001437749-25-006012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/0001437749-25-006012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/allr20250303_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T15:37:55.632839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}